IN2014CN04558A - - Google Patents

Info

Publication number
IN2014CN04558A
IN2014CN04558A IN4558CHN2014A IN2014CN04558A IN 2014CN04558 A IN2014CN04558 A IN 2014CN04558A IN 4558CHN2014 A IN4558CHN2014 A IN 4558CHN2014A IN 2014CN04558 A IN2014CN04558 A IN 2014CN04558A
Authority
IN
India
Prior art keywords
compound
formula
salts
salt
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Bruce D Dorsey
Keith S Learn
Emma L Morris
Gregory R Ott
Jonathan R Roffey
Christelle N Soudy
Jason C Wagner
Original Assignee
Cancer Rec Tech Ltd
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd, Cephalon Inc filed Critical Cancer Rec Tech Ltd
Publication of IN2014CN04558A publication Critical patent/IN2014CN04558A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4558CHN2014 2011-11-23 2012-11-19 IN2014CN04558A (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563310P 2011-11-23 2011-11-23
PCT/US2012/065831 WO2013078126A1 (en) 2011-11-23 2012-11-19 Thienopyrimidine inhibitors of atypical protein kinase c

Publications (1)

Publication Number Publication Date
IN2014CN04558A true IN2014CN04558A (en:Method) 2015-09-18

Family

ID=47295200

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4558CHN2014 IN2014CN04558A (en:Method) 2011-11-23 2012-11-19

Country Status (11)

Country Link
US (3) US9604994B2 (en:Method)
EP (2) EP2782917B1 (en:Method)
JP (1) JP6206926B2 (en:Method)
CN (1) CN104053661B (en:Method)
AU (2) AU2012340869B2 (en:Method)
CA (1) CA2855446C (en:Method)
ES (1) ES2575143T3 (en:Method)
IL (1) IL232559B (en:Method)
IN (1) IN2014CN04558A (en:Method)
MX (1) MX355088B (en:Method)
WO (1) WO2013078126A1 (en:Method)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2802330A4 (en) * 2012-01-10 2015-10-21 Nimbus Iris Inc IRAQ INHIBITORS AND USES THEREOF
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
HK1210732A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2943202A4 (en) 2013-01-10 2016-08-24 Nimbus Iris Inc IRAQ INHIBITORS AND USES THEREOF
US9518065B2 (en) 2013-09-27 2016-12-13 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
TWI675836B (zh) 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶c之氮雜喹唑啉抑制劑
EP3394056B1 (en) * 2015-12-22 2021-04-14 Shy Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
KR20180075228A (ko) * 2016-12-26 2018-07-04 한미약품 주식회사 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체
EP3642209B1 (en) * 2017-06-21 2023-11-29 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2019119206A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CN108658999B (zh) * 2018-04-24 2021-02-05 温州大学 2-苯基杂环并[2,3-d]嘧啶-4(3H)-酮类化合物的合成方法
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
US12246009B2 (en) * 2018-11-20 2025-03-11 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
EP3725788A1 (en) 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
CN116410205B (zh) * 2021-12-29 2024-07-05 上海皓元生物医药科技有限公司 一种3-取代-9-甲基-噻吩并三唑并噁嗪类化合物的制备方法
CN116925098A (zh) * 2022-04-09 2023-10-24 深圳湾实验室 靶向泛素特异性蛋白酶1(usp1)的小分子抑制剂及其应用
WO2025085725A1 (en) * 2023-10-20 2025-04-24 Scorpion Therapeutics, Inc. Methods for treating a p53-associated cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
TW564247B (en) 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
NZ517575A (en) 1999-09-30 2004-04-30 Neurogen Corp Certain alkylene diamine-substituted heterocycles
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
CA2423981A1 (en) 2000-09-29 2003-03-28 Kimiko Ichikawa Thienopyrimidine compounds and salts thereof and process for the preparation of the same
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
MXPA04005510A (es) 2001-12-07 2006-02-24 Vertex Pharma Compuestos basados en pirimidina utiles como inhibidores de gsk-3.
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
TW200410975A (en) 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
WO2004111057A1 (en) 2003-06-11 2004-12-23 Xention Discovery Limited Thienopyrimidine derivatives as potassium channel inhibitors
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005123087A2 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
WO2006093518A2 (en) 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
WO2006010568A2 (de) 2004-07-23 2006-02-02 Curacyte Discovery Gmbh Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung
DE102005013621A1 (de) 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AU2007243457B2 (en) 2006-04-26 2012-02-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
WO2008037607A1 (de) 2006-09-25 2008-04-03 Basf Se Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
ZA200904531B (en) * 2006-12-07 2010-09-29 Hoffmann La Roche Phosphoinositide 3-kinase inhibitor compounds and methods of use
EP2334380B1 (en) 2008-05-30 2021-09-01 Mitologics Ant-ligands molecules and biological applications
SI2385832T1 (sl) * 2009-01-08 2015-10-30 Curis, Inc. Fosfoinozitid 3-kinazni inhibitorji s cinkovim vezavnim delom
KR101675614B1 (ko) 2009-10-29 2016-11-11 벡투라 리미티드 Jak3 키나아제 저해제로서의 n―함유 헤테로아릴 유도체
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
EP2782917A1 (en) 2014-10-01
CN104053661A (zh) 2014-09-17
EP2782917B1 (en) 2016-03-02
AU2017203725A1 (en) 2017-06-22
US10954251B2 (en) 2021-03-23
MX355088B (es) 2018-04-04
US9604994B2 (en) 2017-03-28
IL232559B (en) 2018-04-30
IL232559A0 (en) 2014-06-30
JP6206926B2 (ja) 2017-10-04
CN104053661B (zh) 2018-06-19
US20140323435A1 (en) 2014-10-30
US20190106433A1 (en) 2019-04-11
CA2855446C (en) 2021-04-20
JP2014533728A (ja) 2014-12-15
CA2855446A1 (en) 2013-05-30
AU2017203725B2 (en) 2019-02-28
ES2575143T3 (es) 2016-06-24
AU2012340869B2 (en) 2017-03-02
NZ625447A (en) 2015-09-25
AU2012340869A1 (en) 2014-06-19
EP3048106B1 (en) 2019-11-06
US20170158706A1 (en) 2017-06-08
HK1202529A1 (zh) 2015-10-02
MX2014006233A (es) 2014-10-17
WO2013078126A1 (en) 2013-05-30
US10183950B2 (en) 2019-01-22
EP3048106A1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
IN2014CN04558A (en:Method)
PH12015500689B1 (en) Azaquinazoline inhibitors of atypical protein kinase c
UA110338C2 (xx) Хімічні сполуки
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
PH12015501316A1 (en) Heterocyclic compound
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
MY172924A (en) Neprilysin inhibitors
PH12014502733A1 (en) Neprilysin inhibitors
MX377600B (es) Estimuladores de sgc.
MX2013008162A (es) Inhibidores de pirimidina y topoisomerasa iv.
UA115052C2 (uk) Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
NZ707308A (en) Malononitrile compounds for controlling animal pests
MX2015007568A (es) Compuestos de malononitrilo para controlar plagas de animales.
IN2013MU03015A (en:Method)
EP2807191B8 (en) Methods of treating pain by inhibition of vgf activity
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1